Nova Eye Medical Limited (ASX:EYE)
Australia
· Delayed Price · Currency is AUD 0.147
+0.002 (1.38%)
Mar 10, 2026, 11:20 AM AEST
Nova Eye Medical Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Operating Revenue | 33.05 | 29.27 | 23.33 | 17.03 | 13.38 | 13.39 | Upgrade
|
| Revenue | 33.05 | 29.27 | 23.33 | 17.03 | 13.38 | 13.39 | Upgrade
|
| Revenue Growth (YoY) | 26.59% | 25.47% | 37.00% | 27.26% | -0.12% | 4.51% | Upgrade
|
| Cost of Revenue | 11 | 10.38 | 6.5 | 2.63 | 2.29 | 2.24 | Upgrade
|
| Gross Profit | 22.05 | 18.89 | 16.83 | 14.39 | 11.09 | 11.15 | Upgrade
|
| Selling, General & Admin | 20.85 | 19.63 | 16.8 | 21.87 | 17.4 | 13.21 | Upgrade
|
| Research & Development | 3.17 | 3.24 | 3.97 | - | - | - | Upgrade
|
| Other Operating Expenses | 5.1 | 5 | 5.03 | 2.01 | 1.58 | 1.39 | Upgrade
|
| Operating Expenses | 29.12 | 27.87 | 25.8 | 26.17 | 20.79 | 16.12 | Upgrade
|
| Operating Income | -7.07 | -8.99 | -8.97 | -11.78 | -9.7 | -4.97 | Upgrade
|
| Interest Expense | -0.18 | -0.16 | -0.07 | -0.05 | -0.06 | -0.07 | Upgrade
|
| Interest & Investment Income | 0.09 | 0.08 | 0.12 | 0.1 | 0.03 | 0.24 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | 0.14 | -0.05 | -0.48 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.14 | - | 0.13 | 0.63 | 0.54 | 0.03 | Upgrade
|
| EBT Excluding Unusual Items | -7.03 | -9.06 | -8.79 | -10.96 | -9.24 | -5.25 | Upgrade
|
| Asset Writedown | - | - | - | -6.04 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | 1.42 | - | Upgrade
|
| Pretax Income | -7.03 | -9.06 | -8.79 | -17 | -7.82 | -5.25 | Upgrade
|
| Income Tax Expense | - | - | - | -1.71 | -0.32 | -0.89 | Upgrade
|
| Earnings From Continuing Operations | -7.03 | -9.06 | -8.79 | -15.29 | -7.5 | -4.36 | Upgrade
|
| Net Income | -7.03 | -9.06 | -8.79 | -15.29 | -7.5 | -4.36 | Upgrade
|
| Net Income to Common | -7.03 | -9.06 | -8.79 | -15.29 | -7.5 | -4.36 | Upgrade
|
| Shares Outstanding (Basic) | 275 | 247 | 204 | 156 | 145 | 144 | Upgrade
|
| Shares Outstanding (Diluted) | 275 | 247 | 204 | 156 | 145 | 144 | Upgrade
|
| Shares Change (YoY) | 23.07% | 21.16% | 30.89% | 7.83% | 0.69% | 0.03% | Upgrade
|
| EPS (Basic) | -0.03 | -0.04 | -0.04 | -0.10 | -0.05 | -0.03 | Upgrade
|
| EPS (Diluted) | -0.03 | -0.04 | -0.04 | -0.10 | -0.05 | -0.03 | Upgrade
|
| Free Cash Flow | -5.21 | -6.45 | -8.07 | -7.09 | -4.85 | -13.53 | Upgrade
|
| Free Cash Flow Per Share | -0.02 | -0.03 | -0.04 | -0.04 | -0.03 | -0.09 | Upgrade
|
| Gross Margin | 66.71% | 64.54% | 72.15% | 84.55% | 82.89% | 83.25% | Upgrade
|
| Operating Margin | -21.40% | -30.70% | -38.47% | -69.19% | -72.50% | -37.07% | Upgrade
|
| Profit Margin | -21.27% | -30.95% | -37.69% | -89.83% | -56.03% | -32.52% | Upgrade
|
| Free Cash Flow Margin | -15.77% | -22.03% | -34.59% | -41.63% | -36.27% | -100.99% | Upgrade
|
| EBITDA | -3.88 | -6.72 | -5.98 | -9.48 | -7.89 | -3.45 | Upgrade
|
| EBITDA Margin | -11.75% | -22.97% | -25.66% | -55.69% | -58.96% | -25.76% | Upgrade
|
| D&A For EBITDA | 3.19 | 2.26 | 2.99 | 2.3 | 1.81 | 1.52 | Upgrade
|
| EBIT | -7.07 | -8.99 | -8.97 | -11.78 | -9.7 | -4.97 | Upgrade
|
| EBIT Margin | -21.40% | -30.70% | -38.47% | -69.19% | -72.50% | -37.07% | Upgrade
|
| Advertising Expenses | - | - | - | 3.2 | 1.78 | 0.73 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.